The recent litigation concerning the government’s 340B Rebate Model Pilot Program (the Rebate Program), as further described ...

On February 2, 2024, the “gang of six”—a bipartisan group of six senators who have traditionally championed reforms to the 340B program 1 —introduced a discussion draft of a bill that would modify the ...

The American Hospital Association (AHA) expresses serious concerns with the recent announcement by Eli Lilly and Company (Lilly) to require 340B covered entities to submit claims data for all ...

Senator calls on Congress to increase oversight of the 340B Drug Pricing Program by requiring participating providers to complete annual reports on program savings and revenues. If your health system ...

Regulators on Thursday finalized a flurry of rules with sweeping implications for U.S. providers, including Medicare reimbursement rates for hospital outpatient sites and doctor’s offices and a ...

Hospitals are up in arms over new guidance issued by the Health Resources and Services Administration on Thursday that could restrict the eligibility of their outpatient clinics for drug discounts in ...

The Patient Protection and Affordable Care Act is expected to bring significant change to the healthcare industry, including the expansion of the Public Health Service Act Section 340B Program.

A federal court has blocked the implementation of the 340B rebate pilot, sparing safety-net hospitals from potential cash-flow crises and preserving upfront drug discounts for now. Revenue cycle ...

The drug industry and hospitals have been butting heads over the future of a federal drug pricing program for more than a year, according to The Washington Post. Federal regulators may finalize ...

The 340B drug pricing program is complicated. A clinic leader and a hospital said that’s making it easy for there to be misunderstandings about if the savings are being passed onto the patient.

Rescription, Inc., a leading innovator in pharmacy benefit management, is proud to announce it has been awarded a U.S.

The AHA Jan. 26 urged the Health Resources and Services Administration to take immediate action to stop a new Eli Lilly and ...